A CHO stable pool production platform for rapid clinical development of trimeric SARS‐CoV‐2 spike subunit vaccine antigens
Biotechnology and Bioengineering · 2023
DOI: 10.1002/bit.28387 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Bioengineering, 2023. Verfasst von Simon Joubert und 22 weiteren Autor:innen. Beteiligte Einrichtung: Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Protein expression from stably transfected Chinese hamster ovary (CHO) clones is an established but time‐consuming method for manufacturing therapeutic recombinant proteins. The use of faster, alternative approaches, such as non‐clonal stable pools, has been restricted due to lower productivity and longstanding regulatory guidelines. Recently, the performance of stable pools has improved dramatically, making them a viable option for quickly producing drug substance for GLP‐toxicology and early‐phase clinical trials in scenarios such as pandemics that demand rapid production timelines. Compared to stable CHO clones which can take several months to generate and characterize, stable pool development can be completed in only a few weeks. Here, we compared the productivity and product quality of trimeric SARS‐CoV‐2 spike protein ectodomains produced from stable CHO pools or clones. Using a set of biophysical and biochemical assays we show that product quality is very similar and that CHO pools demonstrate sufficient productivity to generate vaccine candidates for early clinical trials. Based on these data, we propose that regulatory guidelines should be updated to permit production of early clinical trial material from CHO pools to enable more rapid and cost‐effective clinical evaluation of potentially life‐saving vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, Québec, Canada.
- Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
- Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada.
ORCID-Profile: Simon Joubert, Matthew Stuible, Yves Durocher
Zitieren
APA
Joubert, S., Stuible, M., Lord-Dufour, S., Lamoureux, L., Vaillancourt, F., Perret, S., Ouimet, M., Pelletier, A., Bisson, L., Mahimkar, R., Pham, P. L., L Ecuyer-Coelho, H., Roy, M., Voyer, R., Baardsnes, J., Sauvageau, J., St-Michael, F., Robotham, A., Kelly, J., …, & Durocher, Y. (2023). A CHO stable pool production platform for rapid clinical development of trimeric SARS‐CoV‐2 spike subunit vaccine antigens. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28387
Vancouver
Joubert S, Stuible M, Lord-Dufour S, Lamoureux L, Vaillancourt F, Perret S, et al. A CHO stable pool production platform for rapid clinical development of trimeric SARS‐CoV‐2 spike subunit vaccine antigens. Biotechnology and Bioengineering. 2023. doi:10.1002/bit.28387
BibTeX
@article{Joubert2023,
author = {Joubert, Simon and Stuible, Matthew and Lord-Dufour, Simon and Lamoureux, Linda and Vaillancourt, François and Perret, Sylvie and Ouimet, Manon and Pelletier, Alex and Bisson, Louis and Mahimkar, Rohan and Pham, Phuong Lan and L Ecuyer-Coelho, Helene and Roy, Marjolaine and Voyer, Robert and Baardsnes, Jason and Sauvageau, Janelle and St-Michael, Frank and Robotham, Anna and Kelly, John and Acel, Andrea and Schrag, Joseph D and El Bakkouri, Majida and Durocher, Yves},
title = {A CHO stable pool production platform for rapid clinical development of trimeric SARS‐CoV‐2 spike subunit vaccine antigens},
journal = {Biotechnology and Bioengineering},
year = {2023},
doi = {10.1002/bit.28387}
}
EUVIMED